Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 19/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021719 | 0.86 | NR1I2 (0.75) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL15022481 | 0.85 | NR1I2 (0.73) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL898907 | 0.82 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL899035 | 0.82 | NR1I2 (0.69) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL899884 | 0.82 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL899560 | 0.81 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL15032763 | 0.78 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL15021702 | 0.78 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL898627 | 0.77 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL10081993 | 0.77 | PDE10A (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022060978-A1 | METHODS OF TREATING PARKINSON'S DISEASE AND RELATED DISORDERS WITH PDE10A INHIBITORS | MATADOR THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| US-10736894-B2 | Methods of treating developmental syndromes with PDE10A inhibitors | OVID THERAPEUTICS INC. (US) | 2020-08-11 | — | — | US | claimed |
| WO-2019161179-A1 | METHODS OF TREATING DEVELOPMENTAL SYNDROMES WITH PDE10A INHIBITORS | OVID THERAPEUTICS INC. (US) | 2019-08-22 | — | — | WO | claimed |
| US-20190247394-A1 | METHODS OF TREATING DEVELOPMENTAL SYNDROMES WITH PDE10A INHIBITORS | OVID THERAPEUTICS INC. | 2019-08-15 | — | — | US | claimed |
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | claimed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | claimed |
| EP-2621276-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | claimed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | claimed |
| WO-2012044561-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | claimed |
| WO-2022060978-A1 | METHODS OF TREATING PARKINSON'S DISEASE AND RELATED DISORDERS WITH PDE10A INHIBITORS | MATADOR THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-10736894-B2 | Methods of treating developmental syndromes with PDE10A inhibitors | OVID THERAPEUTICS INC. (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2019161179-A1 | METHODS OF TREATING DEVELOPMENTAL SYNDROMES WITH PDE10A INHIBITORS | OVID THERAPEUTICS INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190247394-A1 | METHODS OF TREATING DEVELOPMENTAL SYNDROMES WITH PDE10A INHIBITORS | OVID THERAPEUTICS INC. | 2019-08-15 | — | — | US | disclosed |
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2621276-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2012044561-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | PDE10A, PDE11A, PDE12 | NR1I2 4311/4885CYP3A4 3247/4885CYP2C9 2563/4885 |
| US-20190247394-A1 | METHODS OF TREATING DEVELOPMENTAL SYNDROMES WITH PDE10A INHIBITORS | PDE1B, PDE1A, PDE7B | NR1I2 4076/4885CYP3A4 4840/4885CYP2C9 4707/4885 |
| US-10736894-B2 | Methods of treating developmental syndromes with PDE10A inhibitors | PDE1B, PDE1A, PDE7B | NR1I2 4076/4885CYP3A4 4840/4885CYP2C9 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.